

**FACSIMILE COVER SHEET**

Date: December 10, 2007

To: Examiner Karen M. Reichle  
Company: United States Patent & Trademark Office  
Fax No: 571-273-4936From: Lawrence G. Almeda  
Tel. No: 734-302-6019  
Email: [lalmeda@usebrinks.com](mailto:lalmeda@usebrinks.com)

No. of Pages (including this page): 12

Confirmation Copy to Follow:  Yes, Via  No

ANY PROBLEMS RECEIVING THIS FAX, CALL 734-302-6000.

THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. IT MAY CONTAIN PRIVILEGED, CONFIDENTIAL, ATTORNEY WORK PRODUCT, OR TRADE SECRET INFORMATION WHICH IS EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAWS. IF YOU ARE NOT THE INTENDED RECIPIENT, OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS MESSAGE IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE (AND ALL COPIES) TO US BY MAIL AT THE ADDRESS NOTED BELOW. WE WILL REIMBURSE YOU FOR POSTAGE.

**COVER MESSAGE:**

Re: USSN: 10/737,313 filed December 16, 2003  
Docket No.: 8627-454 (PA-5379-CON)

**BRINKS**  
**HOFER**  
**GILSON**  
**& LIONE**®

A Professional Corporation

Intellectual Property  
Law Worldwide

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: THOMAS A. OSBORNE ET AL.

Appln. No.: 10/737,313

Filed: 12/16/2003

For: HEMOSTASIS CANNULA

Attorney Docket No: 8627-454 (PA-5379-CON)

Examiner: Karin M. Reichle

Art Unit: 3761

## SUPPLEMENTAL RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

This paper is responsive to the Notice of Non-Compliant Amendment mailed 09/07/2007. By this paper and responsive to the Notice, Applicants respectfully submit this paper comprising the following parts:

- I. Listing of Claims, beginning on page 2;
- II. Amendments to Specification, beginning on page 8; and
- III. Remarks, beginning on page 10.

Applicants note that the Transmittal to which this paper is attached includes a Certificate under 37 C.F.R §1.8; and a fee statement calculating any fee(s) presently due in connection with the filing of this paper, along with an authorization to charge any fee deficiency to Deposit Account No. 23-1925.